More Post from the Author
- Johnny Lieberman of Harbor IT named Entrepreneur Of The Year 2026 New York finalist by EY US
- LITO Announces New Collaboration Bringing Exclusive Contemporary Artist Editions to Sotheby's Online Marketplace
- SIRUI Wins "Best of Show", Unveils New Cine Lenses at NAB Show 2026
- Akemona to Power Upcoming Tokenized Offering for Industrialized Innovation Impact Portfolio I
- La vacunacin materna contra el VRS reduce el riesgo de hospitalizacin infantil en ms del 80%
In light of the recent PGT-A class action lawsuit filings in a court in Florida, Vitrolife Group issues the following statement
GOTHENBURG, Sweden, March 5, 2025 /PRNewswire/ -- Vitrolife Group is aware that a PGT-A class action lawsuit has been filed against Vitrolife AB (publ), Vitrolife Inc and Igenomix USA, Inc in the court of the Southern District of Florida, although no formal complaint has been served yet. During the fourth quarter of 2024, similar class actions were initiated in the US against other peer companies providing PGT-A testing services. Vitrolife Group will, together with our legal counsel in the US, evaluate the class action and its potential scope and update the market in due course when further information is available.
Gothenburg, 5 March 2025
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO
Contact:
Amelie Wilson, Investor Relations, [emailprotected]
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
In light of the recent PGT-A class action lawsuit filings in a court in Florida, Vitrolife Group issues the following statement |
SOURCE Vitrolife AB (publ)

More Post from the Author
- Johnny Lieberman of Harbor IT named Entrepreneur Of The Year 2026 New York finalist by EY US
- LITO Announces New Collaboration Bringing Exclusive Contemporary Artist Editions to Sotheby's Online Marketplace
- SIRUI Wins "Best of Show", Unveils New Cine Lenses at NAB Show 2026
- Akemona to Power Upcoming Tokenized Offering for Industrialized Innovation Impact Portfolio I
- La vacunacin materna contra el VRS reduce el riesgo de hospitalizacin infantil en ms del 80%
